#DEXCOM GESTR BLUETOOTH#

Is there any evolution with the readout frequency (to be more frequent than every 5 minutes)? Connected systems are truly the future of diabetes technology and we are working to extend our leadership in the category with these key partners and the tools that we have created to support these integrations, including our Dexcom artificial pancreas algorithm technology.” Two years ago we stated that we believe that by 2023, 50% of our insulin intensive customer base will be using a connected insulin delivery device in combination with our CGM, and we believe that we are on track to hit that mark.

#DEXCOM GESTR BLUETOOTH#

We are also very excited about the development progress that Lilly and Novo Nordisk are making in their Bluetooth connected smart pen technology and we continue to believe that the solutions we’re working on with those two teams will enable significant improvements in the user experience and ease the burden of diabetes in the MDI population, which represents the vast majority of intensive insulin users across the world. With Insulet’s Omnipod 5 preparing for a first half of 2021 launch, we feel that our leadership in this category will result in us having integrations with the leading tethered pump on the market in Tandem’s Control.IQ, and the leading tubeless pump in Omnipod 5. “As the first iCGM on the market, and still the only one indicated for use with automated insulin delivery systems, Dexcom G6 is the forerunner in the category of interoperability and are advocates of patient choice in insulin delivery. “The disposable aspect of the product has no impact on reimbursement.”ĭo you anticipate working on integration with all the major pump companies? Now that the product is disposable, would this no longer be considered durable medical equipment (DME) and thus covered differently by insurance companies? Pharmacy is our preferred distribution channel and we have expanded pharmacy access for Dexcom CGM by nearly 80% since December 2018. “We continue to focus on making CGM more accessible and easier to obtain for patients. Dexcom’s research confirmed the option was highly valued.” Calibration for G7 is the same as G6 it’s factory calibrated, but there will still be the option for users to calibrate if they want. Without further adieu, here are your questions about the G7 answered: Many follow-up questions from our readers prompted us to follow-up further. Last month, we chatted with Jake Leach, Dexcom’s chief technology officer (CTO) to get the latest scoop on the release timeline and new features of the Dexcom G7 continuous glucose monitor (CGM), a highly-anticipated diabetes technology that will be released in 2021. It does not store any personal data.* Editor’s note: This article was updated for clarity on The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category 'Performance'.

This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category 'Other. The cookies is used to store the user consent for the cookies in the category 'Necessary'. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category 'Functional'. The cookie is used to store the user consent for the cookies in the category 'Analytics'. These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly.

Vice President – Finance and Investor Relations For more information about Dexcom CGM, visit Contacts By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.ĭexCom, Inc. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. The conference call will be concurrently webcast. Management will hold a conference call to review the company’s first quarter 2023 performance starting at 4:30 p.m. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023.

Dexcom gestr